

EMPTY BOTTLES, RISING RISKS: A CASE-CROSSOVER STUDY ON

EPH67

PSYCHOTHERAPEUTIC MEDICATION DEPLETION AND SUICIDE TRIGGERS

Austin Porter, DrPH, MPH; Allen M. Smith, PharmD; Srinivasa B. Gokarakonda, MD, MPH; Michael P. Wilson, MD, PhD; and Bradley C. Martin, PharmD, PhD

University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR, 72205, USA

BACKGROUND

Mental health disorders, such as depression, substance use disorders, and schizophrenia are established risk factors for suicide.¹ There is established literature to indicate that adherence to these psychotherapeutics are associated with a reduction in the long-term risk of suicide.³ However, the impact of discontinuing or running out of these medications as a potential trigger for suicide has not been thoroughly investigated. A "trigger" is an acute event or transient encounter that leads to a final outcome or disease. One approach to investigating triggers is to compare exposure to a trigger during a designated "hazard window," occurring immediately prior to the outcome event to a series of "control windows," which are windows of time preceding the hazard window

Using insurance claims data linked to death certificates from 2013-2021, this study investigated the immediate connection between depleting at least one mental health-related medication and suicide.

METHODS

Data Source

- Arkansas All-Payers Claims Database (AR-APCD)
 - Medical and pharmacy claims
- Death certificates

Study Subjects

- All decedents of suicide identified from the death certificate who had:
- i. ≥ 1 psychotherapeutic prescription filled during study window (12 weeks before death)
- ii. Continuous representation in AR-APCD 12 weeks prior to death

Psychotherapeutic Drug Definitions

- Categorized using National Drug Codes (NDC)
 - First Data Bank® ontology scheme
- Psychotherapeutics drugs: Antidepressants, anxiolytics, anti-psychotics

Case-crossover Design

- Hazard window: week before death by suicide
- Control windows: 11-week long periods preceding hazard window

Control Control Window Window Window 11 10 9 8 7 6 5 4 Suicide Window Wi

Each window is 7 days

Main Exposure Measure: Suicide "Trigger"

- Depleting at least one psychotherapeutic during study window
 - Identified as a gap between run-out dates (prescription fill date + days supplied) and prescription fill dates of ensuing prescriptions accounting for early refills

Time Varying Covariates:

- Medical claims used to categorize healthcare utilization before suicide
 - Mental health-related: 290-319 (ICD-9-CM) or F01-F99 (ICD-10-CM)
 - Non-mental health-related: all other ICD-9-CM or ICD-10-CM codes
- Facility codes used to determine location of treatment as inpatient or outpatient
- Four categories of healthcare utilization: (i) Inpatient mental health-related, (ii) Outpatient mental health-related, (iii) Inpatient non-mental health-related, and (iv) Outpatient non-mental health-related
- Time invariant covariates (i.e. gender, comorbidities) were not considered because the casecrossover design controls for time invariant confounding

Analysis

- Conditional logistic regression analysis: healthcare utilization included in model
- Sensitivity analysis conducted by changing study windows from 7 days to 3 days


RESULTS

A total of 853 decedents met the inclusion criteria for this study had a total of 4,375 prescriptions for psychotherapeutic medications to treat mental health conditions during the study windows


Decedent Demographics, Insurance Coverage and Health Care Contacts

VARIABLE	TOTAL POPULATION (N=853)	EXHAUSTED ANY MEDS DURING HAZARD WINDOW (N=145)	DID NOT EXHAUST ANY MEDS DURING HAZARD WINDOW (N=708)	P-VALUE
AGE IN YEARS, MEAN (STD. DEV.)	51.2 (17.2)	50.0 (17.5)	51.5 (17.2)	0.36
AGE GROUP, N(%)				
0-17	23 (2.7%)	<10	>10	0.24
18-44	275 (32.2%)	46 (31.7%)	229 (32.3%)	0.88
45-64	344 (40.3%)	57 (39.3%)	287 (40.5%)	0.78
65+	211 (24.7%)	36 (24.8%)	175 (24.7%)	0.98
MALE, N(%)	549 (64.4%)	88 (60.7%)	461 (65.1%)	0.31
RACE, N(%)				
BLACK	29 (3.4%)	<10	>10	0.14
WHITE	815 (95.6%)	140 (96.6%)	675 (95.3%)	0.66
OTHER	<10	<10	<10	0.07
MISSING	<10	0 (0.0%)	<10	-
MARITAL STATUS				
DIVORCED	260 (30.5%)	46 (31.7%)	214 (30.2%)	0.69
MARRIED	312 (36.6%)	60 (41.4%)	252 (35.6%)	0.17
SINGLE	195 (22.9%)	29 (20.0%)	166 (23.5%)	0.38
WIDOWED	78 (9.1%)	<10	>10	0.10
MISSING	<10	<10	<10	-
MECHANISM, N(%)				
FIREARM	481 (56.4%)	72 (49.7%)	409 (57.8%)	0.07
POISONING	193 (22.6%)	40 (27.6%)	153 (21.6%)	0.12
SUFFOCATION	128 (15.0%)	27 (18.6%)	101 (14.3%)	0.18
OTHER	51 (6.0%)	<10	>10	0.30
INSURANCE TYPE				
MEDICAID	167 (19.6%)	29 (20.0%)	138 (19.5%)	0.88
MEDICARE/MEDICARE				
ADVANTAGE	472 (55.3%)	73 (50.3%)	399 (56.4%)	0.18
PRIVATE/COMMERCIAL	178 (20.9%)	38 (26.2%)	140 (19.8%)	0.08
OTHER	36 (4.2%)	<10	>10	0.61
HEALTHCARE CONTACTS IN HAZARD WINDOW				
ANY CONTACT	316 (37.1%)	58 (40.0%)	258 (36.4%)	0.42
MENTAL HEALTH CLAIM FILED	128 (15.0%)	25 (17.2%)	103 (14.6%)	0.41
NO MENTAL HEALTH CLAIM FILED	260 (30.5%)	44 (30.3%)	216 (30.5%)	0.97


Proportion of Study Population that Exhausted At Least One Mental Health-Related Medication, By Time Window



Conditional Logistic Regression Results Examining the Influence of Exhausting Psychotherapeutic Medications



Proportion of Study Population with a Medical Claim from Any Provider, By Time Window and Claim Type



- √ There is a strong temporal relationship between exhausting psychotherapeutic medications and fatal suicide.
- ✓ There was a 46% increase in the odds of exhausting at least one psychotherapeutic during the hazard window compared to the control windows (p=0.0001)
- There was a 57% decrease in the odds of an outpatient mental health-related encounter during the hazard window compared to the control windows (p<0.0001)
- ✓ Increased odds of both inpatient and outpatient non-mental-related encounter during hazard window
- ✓ Among subset of psychotherapeutics, exhausting anxiolytics had the greatest effect
- ✓ Patients who are treated with psychotherapeutic medications must be followed closely to ensure adequate supply of their psychotherapeutic medications

References

- 1. Ferrari, A. J., Norman, R. E., Freedman, G., Baxter, A. J., Pirkis, J. E., Harris, M. G., Page, A., Carnahan, E., Degenhardt, L., Vos, T., & Whiteford, H. A. (2014). The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study
- 2010. PLOS ONE, 9(4), e91936. https://doi.org/10.1371/journal.pone.0091936
 Cibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2005). The Relationship Between Antidepressant Medication Use and Rate of Suicide. Archives of

nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology and Drug Safety, 17(7), 686-696. https://doi.org/10.1002/pds.1579

- General Psychiatry, 62(2), 165–172. https://doi.org/10.1001/archpsyc.62.2.165
 Haukka, J., Tiihonen, J., Härkänen, T., & Lönnqvist, J. (2008). Association between medication and risk of suicide, attempted suicide and death in
- Access to the AR-APCD for this study was provided by support from the Arkansas Biosciences Institute/Arkansas Insurance Department/Arkansas Healthcare Transparency Initiative Collaboration